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Abstract
Background: Chikungunya virus (CHIKV) has been responsible for large epidemic outbreaks causing fever,
headache, rash and severe arthralgia. So far, no specific treatment or vaccine is available. As nucleic acid
amplification can only be used during the viremic phase of the disease, serological tests like neutralization assays
are necessary for CHIKV diagnosis and for determination of the immune status of a patient. Furthermore,
neutralization assays represent a useful tool to validate the efficacy of potential vaccines. As CHIKV is a BSL3 agent,
neutralization assays with infectious virus need to be performed under BSL3 conditions. Our aim was to develop a
neutralization assay based on non-infectious virus replicon particles (VRPs).
Methods: VRPs were produced by cotransfecting baby hamster kidney-21 cells with a CHIKV replicon expressing
Gaussia luciferase (Gluc) and two helper RNAs expressing the CHIKV capsid protein or the remaining structural
proteins, respectively. The resulting single round infectious particles were used in CHIKV neutralization assays using
secreted Gluc as readout.
Results: Upon cotransfection of a CHIKV replicon expressing Gluc and the helper RNAs VRPs could be produced
efficiently under optimized conditions at 32°C. Infection with VRPs could be measured via Gluc secreted into the
supernatant. The successful use of VRPs in CHIKV neutralization assays was demonstrated using a CHIKV neutralizing
monoclonal antibody or sera from CHIKV infected patients. Comparison of VRP based neutralization assays in
24- versus 96-well format using different amounts of VRPs revealed that in the 96-well format a high multiplicity of
infection is favored, while in the 24-well format reliable results are also obtained using lower infection rates.
Comparison of different readout times revealed that evaluation of the neutralization assay is already possible at the
same day of infection.
Conclusions: A VRP based CHIKV neutralization assay using Gluc as readout represents a fast and useful method to
determine CHIKV neutralizing antibodies without the need of using infectious CHIKV.
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Background
Chikungunya virus (CHIKV) is an arthropod-borne, enve-
loped virus of the genus Alphavirus, family Togaviridae [1].
The single-stranded RNA genome of positive polarity is
capped at the 5’ end and polyadenylated at the 3’ end. It is
12 kilobases (kb) in length and contains two open reading
frames. The 5’ two-thirds of the genome are directly trans-
lated into the nonstructural proteins (nsP1-4) whereas the
structural proteins (capsid, E1 and E2) and two small cleav-
age products (E3 and 6k) are translated from a subgenomic
RNA, which corresponds to the last third of the genome
[1]. Due to the fact that alphaviruses exhibit a broad host
range (including avian, insect and mammalian cells), high
levels of protein expression and a small genome that is easy
to manipulate, they have been exploited as vectors for for-
eign gene expression or vaccination [2]. This is especially
the case for Sindbis virus (SINV), Semliki Forest virus
(SFV), and Venezuelan equine encephalitis virus (VEEV)
[3-5]. In this context, production of virus replicon particles
(VRPs) has been described, which allows the expression of
foreign genes via so called single round infectious particles.
Besides VRP systems, which are composed of an alphavirus
replicon and one helper RNA that encodes all structural
genes, VRP systems have been established in which the
capsid and envelope helper regions are encoded by two
separate helper RNAs [4,6,7]. This reduces the likelihood of
recombination and renders the production of replication-
proficient viruses (RPVs) negligible, thereby increasing bio-
safety [6,7].
CHIKV was first described in 1953 during an outbreak
in Tanzania, East Africa [8,9]. It came into focus again due
to large-scale epidemics in the Indian Ocean region
starting 2005/2006 [10,11]. Since then further recurring
epidemics have been observed from time to time in Africa,
Indian Ocean Islands, and many parts of South-East Asia
and virus emergence also occurred in European countries,
like Italy and France [12-16]. CHIKV is transmitted to
humans by culicids of the genus Aedes including Aedes
aegypti and Aedes albopictus [17-19]. Infection with the
virus results in Chikungunya fever (CHIKF), which is
characterized by high fever, fatigue, headache, nausea,
vomiting, rash, myalgia and severe arthralgia [8,20,21]. To
date, there is no specific treatment and no licensed vac-
cine available against infection with CHIKV.
To determine the immune status of a patient, a neutra-
lization (NT) assay is necessary. Furthermore, NT assays
represent an important method to validate the efficiency
of potential vaccines during vaccine development. Most
neutralization assays described so far for CHIKV involve
the use of infectious CHIKV particles. Besides plaque re-
duction neutralization assay, NT assays using immu-
nofluorescence or inhibition of the cytopathogenic effect
(CPE) as readouts have been described [22-26]. Recently,
a CHIKV pseudotyped lentiviral vector-based NT assay
was established [27]. The latter circumvents the use of
infectious CHIKV particles and readout was performed
several days after transduction by measuring luciferase
activity in the cells transduced with the CHIKV-
pseudotyped lentiviral vector [27]. The aim of our studies
was to also develop an NT assay for CHIKV infection,
which is independent of infectious particles but in
addition allows a very fast and easy readout. Several re-
porter proteins have been described, which allow to follow
up viral infection or replication. Besides fluorescent pro-
teins reporter proteins based on bioluminescent reactions
are widely used. The latter include for example Renilla (R)
or Firefly (F) luciferase (luc) but also Gaussia luciferase
(Gluc), which in contrast to Rluc and Fluc is secreted into
the supernatant thereby facilitating analyses [28,29].
Hence, we aimed to establish a CHIKVVRP basedNTassay
using the oxidative decarboxylation of coelenterazine cata-
lyzed by secreted Gluc leading to emission of blue light as
readout.
Results
Establishment of CHIKV replicon and helper constructs
For the production of CHIKV replicon particles a split
helper system should be applied since it has been de-
scribed that providing the structural proteins via two
separate helper constructs did not result in detectable
incidental production of infectious particles due to re-
combination [6,7].
A CHIKV replicon was established, in which the struc-
tural genes were replaced by a reporter gene (Figure 1A).
For easy readout, Gluc was chosen as reporter protein,
since it is secreted into the supernatant and therefore
allows easy readout without the need of preparing cell
lysates. Furthermore, two helper plasmids were esta-
blished expressing either the CHIKV capsid protein C
(pChikHelper-C) or the CHIKV envelope proteins p62-
6K-E1 (pChikHelper-E). The helper RNAs contain the 5’
and 3’ CHIKV replication signals and a subgenomic pro-
moter followed by either the capsid gene or the remaining
structural proteins, respectively (Figure 1A). The helper
RNAs as well as the CHIKV replicon RNA can be pro-
duced in vitro from plasmids, which contain these se-
quences under control of an SP6 promoter.
To prove efficient secretion of Gluc from the replicon
in vitro transcribed replicon RNA was electroporated into
baby hamster kidney-21 (BHK-21) cells. After electropo-
ration, increasing amounts of Gluc could be detected over
time in the supernatant demonstrating the efficient repli-
cation and secretion of Gluc of the established CHIKV
replicon (Figure 1B).
Conditions for optimized VRP production
For production of VRPs the CHIKV Gluc replicon was
coelectroporated with the two helper RNAs into BHK-
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21 cells. It has been observed that VRP production is
more efficient at temperatures lower than 37°C. Hence, to
compare VRP production at different temperatures, co-
electroporated cells were incubated at either 37°C or 32°C
and the activity of secreted Gluc was measured in Relative
Light Units (RLUs). Whereas at 37°C Gluc secretion in-
creased over time until 48 h post electroporation before
dropping down again, Gluc levels remained lower and
more constant at lower temperature (Figure 2A). Interest-
ingly, when the supernatants were passaged once on BHK
cells to analyze for produced VRPs it turned out that VRPs
had been released to higher and more constant levels for
the experiment performed at 32°C (Figure 2B). This sug-
gests that although Gluc was more efficiently secreted at
37°C the VRP production was indeed more stable at lower
temperature. Hence, for optimized VRP production, the
coelectroporated cells were incubated at 32°C and VRPs
were harvested at 36 h post electroporation. Harvested
VRPs were purified via a sucrose cushion. As determined
by CHIKV real-time PCR, the 30-fold concentrated VRP
stocks contained around 1 × 109 viral RNA copies/ml.
Comparison of test conditions with regard to VRP
infection rate, plate format and readout time
For comparable analyses same test conditions need to be
applied. These include among others parameters like the
amount of VRPs used in the NT assay as well as the read-
out time or the plate format used. Even though the VRP
concentration in established stocks can be determined via
real-time PCR to calculate defined infection rates it might
be desirable to use the same VRP batch for as many NT
assays as possible. NT assays using different amounts of
VRPs corresponding to multiplicities of infection (MOIs)
of 5, 0.5 and 0.05 calculated based on the determined
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Figure 1 CHIKV VRP system. (A) Schematic presentation of the
CHIKV replicon expressing Gluc marker and the CHIKV helper-C and
helper-E RNAs. Lines represent non-translated regions and boxes
represent translated regions, whereas white boxes indicate
nonstructural proteins and gray boxes indicate structural proteins.
The Gluc reporter is represented as black box. In the helper
constructs 5’ terminal nucleotides of the nsP1 gene important for
RNA replication were retained. Arrows indicate the position of the
subgenomic promoter. The solid black circle at the 5’ end of each
RNA represents the CAP structure; (A)n indicates the poly(A) tail.
(B) Kinetics of Gluc secretion after electroporation of CHIKV replicon
expressing Gluc. In vitro-synthesized replicon RNA was
electroporated into BHK cells and release of Gluc into the
supernatant was measured at the indicated time points.
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Figure 2 Optimum of VRP production. (A) In vitro-synthesized
Gluc replicon RNA was coelectroporated with in vitro-synthesized
helper-C and helper-E RNA and cells were either incubated at 32°C
or 37°C. Supernatants were harvested at the indicated time points
after electroporation and Gluc activity was measured in RLUs.
(B) Same volumes of supernatants harvested at different time points
from the different incubation temperatures in (A) were used to
infect fresh BHK cells at 37°C. At 6 h post infection, Gluc activity was
measured in the supernatant.
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RNA copies in the VRP stock were evaluated. Another
reason for testing also lower MOIs was that this better re-
flects the conditions used in classical plaque neutralization
assays. There, a low MOI needs to be chosen to be able to
count single plaques for readout. Evaluation of different
MOIs was first carried out using the neutralizing mono-
clonal antibody (mAb) D3.62 directed against CHIKV E2
(T. Couderc and M. Lecuit, unpublished data). The re-
spective experiments were performed in either a 24- or
96-well format and readout was done at 6 and 24 h post
VRP infection (Figure 3). To evaluate the neutralization
activity, the infectivity rates measured via Gluc secretion
retained after VRP incubation with the respective antibody
dilution were determined in percent compared to the VRP
only control.
As shown in Figure 3, stepwise neutralization was ob-
served after applying the monoclonal antibody in different
dilutions. In the 24-well format the most consistent data
were obtained when VRPs were used at MOI 5 or MOI
0.5. Decreasing the MOI to 0.05 increased the deviation
from the mean. For the 96-well plate format MOI 5
yielded the most reliable data whereas the number of out-
liers increased at lower MOI. The least reliable data were
obtained in the 96-well format using an MOI of 0.05.
Comparing the data received after evaluating the NT assay
at 6 h post infection (p.i.) versus 24 h p.i. revealed similar
results indicating that the readout of the Gluc VRP assay
readily can be performed within one day.
Similar results were obtained when the same set of con-
ditions was tested using a human serum from a CHIKV
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Figure 3 VRP based NT assay using a monoclonal antibody. Assays were performed in either 24- or 96-well format as indicated. Neutralizing
monoclonal antibody directed against CHIKV E2 protein was serially diluted and preincubated with VRPs corresponding to an MOI of 5, 0.5 or
0.05, respectively. A monoclonal antibody against CHIKV capsid protein was used as control (Neg. mAb). Preincubated samples were used to
infect the BHK cells in the 24- or 96-well plates and readout via Gluc secreted into the supernatant was performed at 6 or 24 h post infection as
indicated. The bar labeled with VRP represents infection with the appropriate amount of VRPs not preincubated with monoclonal antibody. The
bar labeled with Mock represents the background measured in untreated (non-infected) BHK cells. The % infectivity was normalized to VRP
infection without monoclonal antibody incubation. Data represent means and standard deviation of experiments performed in triplicate.
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patient (1753/06) (Figure 4). Using immunofluorescence
analysis, the serum was confirmed to be positive against
CHIKV (see also Figure 5A).
Whereas the human CHIKV patient serum resulted in
dose dependent neutralization, a negative serum from a
healthy person did not show any neutralization activity
(Figure 4). Again, MOI 5 and MOI 0.5 turned out to be
the most applicable conditions in the 24-well format and
MOI 5 yielded the most consistent results in the 96-well
format (Figure 4).
Evaluation of VRP based neutralization assay in
comparison to plaque neutralization assay
To further evaluate the applicability of the established
VRP based NT assay comparison to a classical plaque
neutralization assay based on infectious CHIKV was
drawn. The respective analysis was done using again the
neutralizing monoclonal antibody D3.62, the patient
serum 1753/06, as well as two further sera (662/06 and
575/06) from CHIKV patients diseased during the 2006
epidemic in the Indian Ocean region [30]. All sera as
well as the monoclonal antibody were confirmed to be
reactive against CHIKV using indirect immunofluores-
cence (Figure 5A). The plaque neutralization assay was
performed in a 6-well plate format using 100 plaque
forming units (PFU) per well (Figure 5B), whereas for
the VRP based NT assay both the 24-well and 96-well
format was applied using MOI 5 (Figure 5C). The
neutralization activity of a serum is usually judged by de-
termining the serum dilution, which results in 50 or 80%
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Figure 4 VRP based NT assay using patient serum. Assays were performed in either 24- or 96-well format as indicated. Human serum from a
CHIKV patient was serially diluted and preincubated with VRPs corresponding to an MOI of 5, 0.5 or 0.05, respectively. Preincubated samples were
used to infect the BHK cells in the 24- or 96-well plates and readout via Gluc secreted into the supernatant was performed at 6 or 24 h post
infection as indicated. The bar labeled with VRP represents infection with the appropriate amount of VRPs not preincubated with patient sera.
The bar labeled with Mock represents the background measured in untreated (non-infected) BHK cells. Negative (Neg.) serum from a person not
infected with CHIKV was used as control. The % infectivity was normalized to VRP infection without serum incubation. Data represent means and
standard deviation of experiments performed in triplicate.
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reduction of infectivity (NT50 or NT80 titer, respectively).
When using different methods of NT assays, comparison
of absolute NT50 values is limited due to different test
conditions. However, the order of neutralizing activity
among antisera tested should be the same. Table 1 pro-
vides details on the predicted NT50 values using the data
sets depicted in Figure 5B and 5C. Overall, the NT50 ti-
ters determined via the classical plaque neutralization
assay were lower than those observed in the VRP assays
(Table 1). Nevertheless, the same order with regard to
neutralizing activity of the samples was obtained for all
NT assay types, with the monoclonal antibody neutraliz-
ing the best and serum 575/06 neutralizing the least
(Table 1). This comparison was supported by narrow
95% confidence intervals (CI) determined for each
serum (Table 1). In the 96-well VRP assay format, all
95% CI overlapped partially. In contrast, the 95% CI
overlapped marginally only for two sera in the plaque
assay, and no overlap at all was observed in the 24-well
VRP assay format. Hence, the CHIKV VRP based NT
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assay represents a useful alternative to CHIKV NT as-
says involving infectious virus and in addition allows a
fast and easy analysis of neutralizing antibodies in serum
samples that can be performed within one day.
Discussion
The present study shows that Gluc expressing VRPs rep-
resent a useful tool to determine neutralizing antibodies
without the need of infectious CHIKV particles. VRPs
were produced by cotransfection of a CHIKV replicon ex-
pressing Gluc and two helper RNAs. First studies describ-
ing the production of VRPs involved the cotransfection of
a single helper RNA encoding all structural proteins
[3,31]. However, in this constellation a single RNA recom-
bination event is sufficient to reproduce a full-length gen-
ome resulting in production of infectious particles [31].
Expressing the structural proteins via two helper RNAs
circumvents this problem and it was shown that using this
strategy production of infectious particles due to recom-
bination is negligible [2,6], which is an important aspect
with regard to biosafety issues.
For certain alphaviruses, like SFV and SINV, expres-
sion of the structural proteins was described to be
dependent on an enhancer sequence located in the 5’
terminal part of the sequence encoding the capsid pro-
tein [32,33]. To ensure in these cases efficient translation
of the envelope proteins in a bipartite helper packaging
system, the enhancing sequence of the capsid protein
was fused 5’-terminally to the envelope genes [6,7].
However, for VEEV a split helper system was described
in which the envelope proteins were expressed without a
capsid translation enhancer [4]. The latter implicates
that the enhancer sequence is not necessarily needed in
the VEEV context [4]. This seems to be also the case for
CHIKV, as no stable hairpin structure comparable with
capsid enhancers of SFV and SINV could be predicted in
the corresponding region of the CHIKV genome. Never-
theless, it was also observed that the CHIKV replicon
could be efficiently packed using split helper RNAs of
SFV (A. Merits and A. Lulla, unpublished data). There-
fore the effect of classical SFV capsid enhancer was
tested also in the context of CHIKV helper RNAs. In
this experiment the presence of enhancer sequence not
only failed to increase but reduced the VRP production
(A. Lulla, V. Lulla, unpublished data). Therefore in our
split helper system the helper-E construct used did not
contain any capsid enhancer and still allowed efficient
production of VRPs.
Alphaviruses are known to be transmitted by insect vec-
tors, which exhibit body temperatures below 37°C. Hence,
the VRP production was also tested at lower temperature
and has proven to be more efficient at 32°C than at 37°C.
Reducing the temperature to 28°C even slightly increased
the VRP yield further but simultaneously slowed down the
production process resulting in a prolonged production
time (data not shown).
To facilitate and accelerate the readout of the NT assay
we established a VRP system expressing Gluc, which is se-
creted into the supernatant [28]. Hence, measuring can
directly be performed from the supernatant without the
need of lysing cells. The latter was described to be neces-
sary for the pseudotyped lentiviral vector-based CHIKV
NT assay, which used Fluc as reporter protein [27]. In
addition, the humanized Gluc has been described to be
1000-fold more sensitive compared to humanized Rluc or
Fluc [28,34]. Furthermore, Gluc is very stable (half-life
around 6 days [35]), which allows storage of the super-
natant at 4°C for several days without significantly loosing
activity [28]. On the other hand, due to the high sensitiv-
ity, Gluc reporter assays are likely to be prone to pipetting
errors [28]. Hence, pipetting smaller volumes when work-
ing in the 96-well format at lower MOI might be one
reason for the higher deviations observed in this experi-
mental setup. As already described, it is not recommended
to use a pipetting volume below 10 μl for Gluc assays [28].
Nevertheless, when using an MOI of 5, reliable results
were also obtained in the 96-well format. Using an even
higher MOI is not recommended. Besides consuming ex-
cessive amounts of VRPs, the risk to exhaust the assay ex-
ists. Also, especially at 24 h post infection, the amount of
Gluc released into the supernatant after using an MOI of
50 was so high that samples had to be diluted to allow
Table 1 Neutralizing antibody titers (NT50)
Virus-NTa VRP-NT (24 well)b VRP-NT (96 well)b
mAb/ Serum NT50
c (95% CI)e NT50
d (95% CI) NT50
d (95% CI)
D3.62 16256 (13465 – 19731) 58306 (45196 – 79754) 26885 (22799 – 32054)
1753/06 5978 (4882 – 7350) 16203 (12911 – 20881) 26314 (21004 – 34401)
662/06 3582 (2581 – 5061) 13437 (11819 – 15382) 18743 (15050 – 24194)
575/06 1375 (615 – 2183) 4511 (3590 – 5662) 10911 (7743–15876)
a Neutralization assay performed with virus particles (plaque assay).
b Neutralization assay performed with virus replicon particles (Gluc assay).
c NT50 values were determined via probit analysis using the data set of Figure 5B.
d NT50 values were determined via probit analysis using the data sets of Figure 5C.
e 95% confidence interval.
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measurement of Gluc activity (data not shown). This
could result in an additional source of variation.
The 96-well format might especially be favorable to
use when only small sample volumes are available or
when neutralizing titers have to be determined for an
extensive number of samples. Working in a 96-well for-
mat allows to directly transfer the Gluc containing
supernatant from the NT assay plate to a corresponding
96-well readout plate using a multichannel pipette
thereby avoiding time consuming single pipetting steps.
Furthermore, both the recently described pseudotyped
lentiviral vector-based NT assay [27] and our VRP based
NT assay have the advantage that the use of infectious
CHIKV particles is avoided. However, for the lentiviral
system readout is performed several days after transduc-
tion, whereas our VRP based assay allows carrying out
the NT assay including readout within one day.
Performing different types of NT assays results in fairly
different scales of NT titers. This was also observed
when comparing the lentiviral vector-based NT assay
with a classical plaque neutralization assay [27]. Simi-
larly, the antibody dilutions for which the infectivity was
inhibited by 50% were different for each sample compar-
ing our VRP based assay with a plaque neutralization
assay. Nevertheless, the order of neutralization potency
among the samples was consistent (Table 1) indicating
that the assay is suitable to determine comparative
neutralization activities. Furthermore, the fact that no
infectious CHIKV particles are needed and that readout
can already be performed after 6 h makes the established
Gluc VRP based NT assay a valuable tool to study pa-
tient or animal serum samples. Besides diagnostic pur-
poses, analyses of neutralizing antibodies in human sera
will help to understand immune mechanisms involved in
CHIKV disease and analyses in animals will be useful in
evaluation steps during CHIKV vaccine development.
Conclusions
We have established an NT assay based on CHIKV VRPs
using secreted Gluc as readout. This circumvents the
use of infectious CHIKV and allows an easy readout.
The VRP based assay can be performed in microtiter
plates and readout can be done within a single day mak-
ing it suitable for high-throughput analyses of CHIKV
neutralization antibodies in human or animal sera.
Methods
Cells and viruses
Baby hamster kidney-21 (BHK-21) cells were maintained
in Glasgow´s Minimum Essential Medium (GMEM) sup-
plemented with 5% fetal bovine serum (FBS), 1% L-
glutamine, 10% tryptose phosphate broth, 20 mM HEPES
pH 7.2, 100 U/ml penicillin and 0.1 mg/ml streptomycin
at 37°C and 5% CO2.
A stock of recombinant wild-type CHIKV (CHIKV-
LR2006 OPY1, [36]) was produced on BHK-21 cells. Cells
were infected at an MOI of 0.1 for 1 h and virus harvested
from the supernatant 2 days p.i. was stored at −80°C. Ex-
periments with infectious CHIKV were performed in a
biosafety level 3 laboratory.
Antibodies and antisera
Monoclonal antibody D3.62 (35 mg/ml) is directed against
CHIKV E2 protein (T. Couderc and M. Lecuit, unpublished
data). Human sera containing neutralizing CHIKV anti-
bodies were obtained from patients returning to Europe
from the Indian Ocean region in 2006 and have been de-
scribed previously [30]. Briefly, sera from patient 575/06
returned from the Seychelles, patient 662/06 from La
Réunion and patient 1753/06 from Mauritius. Monoclonal
antibody Z2G2 recognizing CHIKV capsid protein was
kindly provided by Petra Emmerich (Bernhard Nocht
Institute, Hamburg, Germany).
Indirect immunofluorescence
BHK-21 cells were cultured on glass coverslips and
infected with CHIKV-LR2006 OPY1 at an MOI of 0.5. At
24 h after infection, cells were fixed with ice-cold metha-
nol / acetone (1:1) and air-dried. Serum samples or mo-
noclonal antibodies were diluted 1:5000 in PBS and
incubated for 1 h at 37°C on fixed cells. Serum antibodies
were detected by Alexa 488-labeled goat anti-human IgG
(Jackson ImmunoResearch, 1:500) and monoclonal anti-
bodies by cyanine 3-conjugated goat anti-mouse IgG
(Jackson ImmunoResearch, 1:200) using fluorescence mi-
croscopy (Axiovert 40 microscope, Zeiss). Nuclei were
stained with 4',6-diamidino-2-phenylindole (DAPI).
Plasmid constructs
The construction of full-length infectious cDNA of
CHIKV-LR2006 OPY1 is described elsewhere [36]. To ob-
tain plasmid pChikRepl containing the cDNA of a CHIKV
replicon, the region of the infectious cDNA clone corre-
sponding to the coding sequence of CHIKV structural
proteins (nucleotides 7565–11310 of CHIKV-LR2006
OPY1) was replaced with sequence 5’ CCTAGGTAAT
AAGTTTAAAC 3’ (recognition sites of restriction endo-
nucleases AvrII and MssI (PmeI) are underlined) by PCR-
mediated mutagenesis. The coding sequence of Gluc
(optimized for human codon usage, synthesized by
GeneArt (Life Technologies)) was PCR amplified using
primers 5’ TATTCCTAGGCCACCATGGGAGTCAAAG
TTCTGTTTGCC 3’ (start codon is in bold, recognition
site of AvrII restriction enzyme is underlined) and 5’
TGATGTTTAAACTTAGTCACCACCGGCCCCCTTG
ATCTT 3’ (stop codon is in bold, recognition site of
MssI restriction enzyme is underlined); the obtained
fragment was digested with AvrII and MssI enzymes
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(Thermo Scientific, USA) and inserted into pChikRepl
vector digested with the same enzymes. The resulting
plasmid was designated as pChikRepl-Gluc. To obtain a
plasmid, containing the cDNA of a packaging construct
for ChikRepl-Gluc, the region of the infectious cDNA
corresponding to nucleotides 308–7419 of CHIKV-
LR2006 OPY1 [36] was replaced by sequence 5’
GTTTAAAC 3’ (recognition site of MssI restriction en-
zyme) using PCR-mediated mutagenesis; the resulting
plasmid was designated pChikHelper. To obtain plas-
mids for a split helper system the following changes
were introduced into pChikHelper using PCR based
mutagenesis. First, to obtain pChikHelper-E the region
corresponding to nucleotides 461–1248 (coding region
for capsid protein) of pChikHelper was replaced by se-
quence 5’ CCTAGGCCACCATG 3’ (recognition site of
AvrII restriction enzyme is underlined). Second, to obtain
pChikHelper-C the region corresponding to nucleotides
1246–4206 (coding region for E3-E2-E1 glycoproteins) of
pChikHelper was replaced by sequence 5’
TAAGTTTAAAC 3’ (recognition site of MssI restriction
enzyme is underlined). All constructs were verified using
Sanger sequencing. Sequences of all plasmid vectors are
available from authors upon request.
Electroporation and VRP production
Replicon and helper DNA templates were linearized with
NotI and in vitro transcribed using the mMESSAGE
mMACHINE SP6 Kit (Ambion). For recovery of VRPs 1
μg of each, the replicon and helper RNAs, were
coelectroporated into 1 × 106 BHK-21 cells using BHK-
21 preset protocol of Gene Pulser Xcell (Bio-Rad). Cells
were seeded into 25 cm2 flasks and incubated at 32°C
for 36 h. For large-scale VRP production supernatants of
six electroporations were pooled for purification. After
removing detached cells and cell debris by clarifying for
30 min at 4000 g and 4°C, the supernatants were passed
through a 0.45 μm filter and applied to a 20% sucrose
cushion followed by centrifugation for 90 min at 25000
rpm and 4°C (SW 32 Ti rotor, Beckman Coulter). Pellets
were resuspended in TNE buffer (50 mM Tris–HCl, pH
7.4, 100 mM NaCl, 0.5 mM EDTA) over night at 4°C be-
fore passing through a 0.22 μm filter. VRPs were stored
at −80°C.
Real-time reverse transcription-PCR
RNA from VRPs in the cell culture supernatant or after su-
crose cushion purification was extracted using NucleoSpin
RNA Virus Kit (Macherey-Nagel). The isolated RNA was
detected by real-time reverse transcription-PCR (RT-PCR)
using the SuperScript III One-Step RT-PCR System with
Platinum Taq DNA polymerase (Invitrogen). For detection
of CHIKV RNA, the 25 μl reaction contained 3 μl of RNA,
1x Reaction Mix, 0.5 μg BSA, 0.5 μl SS III RT / Platinum
Taq Mix, 0.6 μM of primer CHIKSI, 0.6 μM of primer
CHIKASI and 0.2 μM of the CHIKP probe [30]. Thermo-
cycling was performed on a LightCycler 480 (Roche) pro-
grammed for: 30 min at 50°C for reverse transcription, 2
min at 94°C to activate the Taq polymerase and 45 PCR
amplification cycles of 15 sec at 94°C, 30 sec at 58°C and
30 sec at 72°C. Photometrically quantified in vitro-RNA
transcripts of the target regions were used in the PCR to
generate a standard curve for viral RNA quantification.
Luciferase assay
Gluc was measured from the supernatant of infected cells
using Renilla Luciferase Assay System (Promega) according
to the manufacturer’s instructions. Luciferase activity was
measured in RLUs. Measurement was performed auto-
mated in a Synergy 2 microplate reader (BioTek) using
polystyrol microplates (Greiner Bio-one).
VRP neutralization assay
The day before infection, 24- or 96-well plates were
seeded with 1 × 105 or 2 × 104 BHK-21 cells per well, re-
spectively. VRPs were applied in the NT assay at MOI 5,
0.5 or 0.05 (calculated based on VRP RNA copies/ml). All
dilutions were performed using GMEM supplemented
with 1% FBS. VRP dilutions were incubated with serially
diluted antibody or human serum for 1 h at 37°C before
adding the mixture to a monolayer of BHK-21 cells in
either a 24-well plate (total volume per well 200 μl) or a
96-well plate (total volume per well 40 μl). After incuba-
tion for 1 h at 37°C the inoculum was removed, cells were
washed once with PBS and medium was added. Superna-
tants for Gluc measurement were taken at 6 h and 24 h p.
i. Neutralization potency was determined as percentage of
measured Gluc activity compared to Gluc readout after
VRP application without antibody/serum.
Plaque reduction neutralization assay
About 100 PFU of infectious wild-type virus were incu-
bated with serially diluted antibody or human serum for
1 h at 37°C, added to a monolayer of BHK-21 cells in a
6-well plate (total volume per well 600 μl) and incubated
at 37°C for 1 h. Subsequently, the inoculum was replaced
by an overlay containing 0.6% agarose in MEM. At 48 h
p.i. cells were fixed with 7% formaldehyde and plaques
were visualized using crystal violet staining (1% crystal
violet in 50% ethanol). Neutralization potency was deter-
mined as percentage of plaque titers compared to plaque
titers after virus infection without antibody/serum.
Statistics
Probit analysis for determination of NT50 values was done
with the SPSSV21 software package (IBM, Ehningen,
Germany).
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